46. Malignant rheumatoid arthritis Clinical trials / Disease details


Clinical trials : 4,356 Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02277574
(ClinicalTrials.gov)
June 201423/7/2014Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid ArthritisA Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBiological: AMP-110;Other: PlaceboMedImmune LLCDaiichi Sankyo Co., Ltd.Completed18 Years75 YearsBoth29Phase 1United States
2NCT01878123
(ClinicalTrials.gov)
April 201322/5/2013Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid ArthritisA Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBiological: AMP-110;Other: PlaceboMedImmune LLCDaiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd.Completed18 Years75 YearsBoth26Phase 1United States